The Office of the Inspector General says more needs to be done to keep Medicare patients from using the discount cards.
Patients have to be high-risk or Baby Boomers for coverage.
The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.
Researchers says growth will average 5.8% a year between 2012 and 2022. They also anticipate generics will hit a leveling-off point that will drive average Rx prices upwards
The drug maker asked CMS to approve its Amyvid PET tracer for Medicare beneficiaries, but CMS declined, saying in a draft decision that widespread use would be of little value.
Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva's sales; Study says Medicare patients more likely to receive brand-name medications than VA patients
From FDA and pharma, to Caronia and off-label communication, three healthcare policy experts offer their take on what 2013 holds in store.
The nonpartisan Congressional Budget Office is tallying medical savings differently, adding a new perspective to chatter about the financial implications of nonadherence and rising drug prices.
Nature releases the Antibodypedia's seventh generation, Elsevier adds more board review apps, and how redefining "senior" may not save money in the long run
Barack Obama edged Mitt Romney in fundraising from pharmas in the 2012 election, even as the industry favored Republicans in other contests. Were change-weary drug companies voting for the status quo?
After three years of wrangling, drug companies can again offer co-pay coupons and cards or buy doctors lunch off-site -- with some limitations.
The National Coalition on Health Care took aim at co-pay cards and coupons with a report suggesting that they might push 2 million US seniors to opt for more expensive branded drugs over generics.
Congressional Republicans -- and even a few Democrats -- are pressing the attack on the Independent Payment Advisory Board for Medicare, a part of the Affordable Care Act opposed by both PhRMA and the AMA.
The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.